Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders

VANCOUVER, BC, May 31, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its annual general meeting of shareholders (the "Meeting"), held earlier today.  A total of 50,266,506 common shares representing 15.68% of the 320,551,600 issued and outstanding common shares of the Company as at the record date of April 2, 2024, were represented either in person or by proxy at the Meeting.

The following six nominees proposed by Numinus were elected as directors of Numinus to serve until Numinus' next annual meeting of shareholders, or until their successors are elected or appointed.  Below is a summary of the voting results for the directors elected:

In addition to the election of all nominees listed as directors in the management information circular, dated April 10, 2024 (the "Circular"), Numinus shareholders approved all other resolutions placed before the Meeting, including setting the number of directors of Numinus at six and the appointment of Davidson & Company LLP as auditors for Numinus for the ensuing year.

More information about the resolutions voted on at today's Meeting is available in the Circular, which can be found on SEDAR+ at www.sedarplus.ca.  Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+.

Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research, clinic care and practitioner training – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the risks set forth in our annual information form dated November 29, 2023 and available on SEDAR+ at www.sedarplus.ca. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

SOURCE Numinus Wellness Inc.